Bladder cancer
UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa

Natalia (60 years old)

Natalia, 60 years old, takes pleasure in organising virtual book clubs, where she leads discussions on her favourite novels from the comfort of her cozy armchair.

She was diagnosed with MIBC cT2N1M0 and received 4 cycles of neoadjuvant dose-dense MVAC followed by radical chemoradiotherapy. A second transurethral resection of bladder tumour (TURBT) and random bladder biopsies did not show any residual tumour after chemoradiotherapy. Imaging was suggestive of cT0N0M0. Chemotherapy was well tolerated, with grade 1 neutropenia and grade 1 anaemia.

She presents with lung metastases 15 months after completing neoadjuvant chemotherapy.

Assessment summary:

  • Former smoker (50 pack years)
  • Medical history: chronic obstructive pulmonary disease, hypertension
  • ECOG PS: 0
  • CT scan reveals lung metastases, biopsy compatible with UCa
  • No peripheral neuropathy
  • Audiometric hearing loss: grade 1
  • GFR: 45 ml/min
  • PD-L1 expression: negative
  • FGFR2/3 alteration status in metastatic biopsy specimen: wild type

Which of the following options would you choose for this patient?